跳到正文
原文
ClinicalTrials.gov 临床试验·· 2 天前AI 评分33

Iparomlimab与Tuvonralimab(QL1706)联合局部治疗一线治疗伴门静脉癌栓肝细胞癌的II期研究

A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

AI 导读

一项单臂II期研究计划入组43例未经治疗、伴门静脉癌栓(PVTT)的肝细胞癌患者,评估TAE-HAIC联合Iparomlimab与Tuvonralimab(QL1706,7.5 mg/kg,iv,Q3W)及仑伐替尼(体重<60 kg者8 mg,po,QD)一线治疗。QL1706于介入治疗第2天给药,21天为一周期,HAIC周期由研究者按病情确定,为3至6个周期,QL1706与仑伐替尼最多维持2年。

来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov